196,074 results match your criteria prostate cancer


Oncostatic activities of melatonin: Roles in cell cycle, apoptosis, and autophagy.

Biochimie 2022 May 23. Epub 2022 May 23.

Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran; Department of Clinical Biochemistry, Faculty of Medicine, Golestan University of Medical Sciences, Babol, Iran. Electronic address:

Melatonin, the major secretory product of the pineal gland, not only regulates circadian rhythms, mood, and sleep but also has actions in neoplastic processes which are being intensively investigated. Melatonin is a promising molecule which considered a differentiating agent in some cancer cells at both physiological and pharmacological concentrations. It can also reduce invasive and metastatic status through receptors MT1 and MT2 cytosolic binding sites, including calmodulin and quinone reductase II enzyme, and nuclear receptors related to orphan members of the superfamily RZR/ROR. Read More

View Article and Full-Text PDF

Exposure to greenspace and cancer incidence, prevalence, and mortality: A systematic review and meta-analyses.

Sci Total Environ 2022 May 23:156180. Epub 2022 May 23.

Univ Rennes, INSERM, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France. Electronic address:

We conducted a systematic review and meta-analysis of the available literature on the association between greenspace exposure and all-sites and site-specific cancer incidence, prevalence, and mortality in adults. We searched PubMed, Scopus, and Web of Science for original articles published, without language restriction until September 2021. We assessed the risk of bias in each study and the overall quality of evidence for exposure-outcome pairs that were reported in two or more studies. Read More

View Article and Full-Text PDF

Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial.

Radiother Oncol 2022 May 23. Epub 2022 May 23.

CRUK & UCL Cancer Trials Centre, London, United Kingdom.

Background: Metastatic spinal cord compression (MSCC) carries a poor prognosis and management is based on the likelihood of maintaining mobility and predicted survival.

Patients And Method: SCORAD is a randomised trial of 686 patients comparing a single dose of 8Gy radiotherapy with 20Gy in 5 fractions. Data was split into a training set (412, 60%) and a validation set (274, 40%). Read More

View Article and Full-Text PDF

Economic Cost and Sustainability of Oral Therapies in Precision Oncology.

JCO Oncol Pract 2022 May 26:OP2100847. Epub 2022 May 26.

Mayo Clinic College of Medicine and Science, Rochester, MN.

Purpose: Precision oncology promises improved outcomes but the cost-effectiveness and accessibility of targeted therapies is debatable. We report price change patterns from 2015 to 2019 for several oral anticancer medications for common solid tumor malignancies.

Methods: We collected provider utilization and payment data from the public Medicare Part D database and extracted drug price information for commonly prescribed targeted oral anticancer agents for lung, breast, and prostate cancer. Read More

View Article and Full-Text PDF

Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.

Science 2022 May 27;376(6596):eabe1505. Epub 2022 May 27.

Institute for Computational Biomedicine, Weill Cornell Medical College, New York, NY 10021, USA.

In castration-resistant prostate cancer (CRPC), the loss of androgen receptor (AR) dependence leads to clinically aggressive tumors with few therapeutic options. We used ATAC-seq (assay for transposase-accessible chromatin sequencing), RNA-seq, and DNA sequencing to investigate 22 organoids, six patient-derived xenografts, and 12 cell lines. We identified the well-characterized AR-dependent and neuroendocrine subtypes, as well as two AR-negative/low groups: a Wnt-dependent subtype, and a stem cell-like (SCL) subtype driven by activator protein-1 (AP-1) transcription factors. Read More

View Article and Full-Text PDF

Outcomes of Retzius-sparing versus conventional robot-assisted radical prostatectomy: A KSER update series systematic review and meta-analysis.

PLoS One 2022 26;17(5):e0268182. Epub 2022 May 26.

Department of Urology, Kyung Hee University School of Medicine, Seoul, Korea.

Background: Robotic-assisted radical prostatectomy(RARP) is widely used to surgically treat of localized prostate cancer. Among RARP, retzius-sparing techniques(RS-RARP) are implemented through douglas pouch, not the existing conventional approach(C-RARP). We conducted an updated systematic review and meta-analysis including recent published papers. Read More

View Article and Full-Text PDF

Volumetric modulated arc therapy (VMAT): A review of clinical outcomes- What is the clinical evidence for the most effective implementation?

Br J Radiol 2022 May 26:20201289. Epub 2022 May 26.

Department of Medical Physics & Biomedical Engineering, University College London, London, UK.

Modern conformal radiation therapy using techniques such as modulation, image guidance and motion management have changed the face of radiotherapy today offering superior conformity, efficiency, and reproducibility to clinics worldwide. This review assesses the impact of these advanced radiotherapy techniques on patient toxicity and survival rates reported from January 2017 to September 2020. The main aims are to establish if dosimetric and efficiency gains correlate with improved survival and reduced toxicities and to answer the question 'Has VMAT become the gold standard of radiotherapy?'. Read More

View Article and Full-Text PDF

AZD5305 More Tolerable than 1st-Generation PARP Inhibitors.

Authors:

Cancer Discov 2022 May 26:OF1. Epub 2022 May 26.

Findings from the phase I/IIa trial of AZD5305, a next-generation, highly selective PARP1 inhibitor, indicate that the drug is better tolerated in patients with ovarian, HER2-negative breast, pancreatic, and prostate cancers with BRCA1/2, PALB2, and RAD51C mutations compared with first-generation PARP inhibitors. In addition, 25% of 40 evaluable patients had a partial response. Read More

View Article and Full-Text PDF

Race-specific prostate cancer outcomes in a cohort of low and favorable-intermediate risk patients who underwent external beam radiation therapy from 1990 to 2017.

Cancer Med 2022 May 26. Epub 2022 May 26.

Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.

Background: Previous research exploring the role of race on prostate cancer (PCa) outcomes has demonstrated greater rates of disease progression and poorer overall survival for African American (AA) compared to Caucasian American (CA) men. The current study examines self-reported race as a predictor of long-term PCa outcomes in patients with low and favorable-intermediate risk disease treated with external beam radiation therapy (EBRT).

Methods: This retrospective cohort study examined patients who were consented to enrollment in the Center for Prostate Disease Research Multicenter National Database between January 01, 1990 and December 31, 2017. Read More

View Article and Full-Text PDF

lncRNA MNX1‑AS1 promotes prostate cancer progression through regulating miR‑2113/MDM2 axis.

Mol Med Rep 2022 Jul 26;26(1). Epub 2022 May 26.

Department of Urology Surgery, Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China.

A growing number of dysregulated long non‑coding (lnc)RNAs have been verified to serve an essential role in human prostate cancer. However, the underlying mechanisms of lncRNA MNX1 Antisense RNA 1 (MNX1‑AS1) in prostate cancer has not been explored. Therefore, the present study aimed to explore the function of MNX1‑AS1 in prostate cancer tumorigenesis and investigate the in‑depth mechanism. Read More

View Article and Full-Text PDF

[Corrigendum] HepaCAM inhibits cell proliferation and invasion in prostate cancer by suppressing nuclear translocation of the androgen receptor via its cytoplasmic domain.

Mol Med Rep 2022 Jul 26;26(1). Epub 2022 May 26.

Department of Urology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, P.R. China.

Following the publication of the above article, an interested reader drew to the authors' attention that the western blotting data shown in Figs. 2F and 5E were strikingly similar, even though they were intended to show the results from differently performed experiments; furthermore, the migration assay images shown for the 24 h 'Blank' and 'Vector' experiments in Fig. 3C were apparently the same. Read More

View Article and Full-Text PDF

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy.

JNCI Cancer Spectr 2022 May;6(3)

Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI, USA.

Background: The Timing Of Androgen Deprivation (TOAD) trial found an overall survival benefit for immediate vs delayed androgen deprivation therapy (ADT) for prostate-specific antigen (PSA)-relapsed or noncurable prostate cancer. However, broad eligibility criteria allowed entry of a heterogeneous participant group, including those with prior ADT exposure, raising concerns about subsequent androgen sensitivity. For these reasons, we completed previously specified subgroup analyses to assess if prior ADT was associated with ADT timing efficacy after PSA relapse. Read More

View Article and Full-Text PDF

Antioxidative, anti-inflammatory, and anticancer properties of the red biopigment extract from Monascus purpureus (MTCC 369).

J Food Biochem 2022 May 26:e14249. Epub 2022 May 26.

Department of Applied Sciences and Biotechnology, School of Biotechnology, Shoolini University, Solan, India.

In this study, the Monascus purpureus (MTCC 369) extracted biopigment produced by solid-state fermentation was evaluated for its therapeutic potential using human prostate LNCaP cells. Antioxidant efficacy of the red biopigment determined using 2,2 diphenyl-1-picrylhydrazyl, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid, and ferric reducing antioxidant power assays was found to be 53.16%, 86. Read More

View Article and Full-Text PDF

Synthesis, physicochemical characterization and antiproliferative activity of phosphino Ru(II) and Ir(III) complexes.

Dalton Trans 2022 May 26. Epub 2022 May 26.

ICMATECNR, Corso Stati Uniti 4, 35127 Padova, Italy.

Herein, we present the synthesis of new complexes based on ruthenium(II) (Ru(η--cymene)ClPPhCHOH (RuPOH) and Ru(η--cymene)ClP(-OCHPh)CHOH (RuMPOH)) and iridium(III) (Ir(η-Cp*)ClP(-OCHPh)CHOH (IrMPOH) and Ir(η-Cp*)ClPPhCHOH (IrPOH)) containing phosphine ligands with/without methoxy motifs on phenyl rings (P(-OCHPh)CHOH (MPOH) and PPhCHOH (POH)). The complexes were characterized by mass spectrometry, NMR spectroscopy (1D: H, C{H}, and P{H} and 2D: HMQC, HMBC, and COSY NMR) and elemental analysis. All the complexes were structurally identified by single-crystal X-ray diffraction analysis. Read More

View Article and Full-Text PDF

Growing solitary fibrous tumor of the prostate during COVID-19 pandemic.

Urol Case Rep 2022 May 20:102121. Epub 2022 May 20.

Hospital Universitario Infanta Sofía, Spain.

Solitary fibrous tumor (SFT) is an uncommon neoplasm tipically located on the pleura (Chick et al., 2013 Mar) 1. Althought prostatic cancer tend to be adenocarcinoma, prostatic solitary fibrous tumor might be a rare cause of prostatic growth. Read More

View Article and Full-Text PDF

Statin Use and the Risk of Prostate Cancer Biochemical Recurrence Following Definitive Therapy: A Systematic Review and Meta-Analysis of Cohort Studies.

Front Oncol 2022 9;12:887854. Epub 2022 May 9.

Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Background: Numerous studies have reported the role of statins on biochemical recurrence (BCR) among patients with prostate cancer (PCa) after definite treatment. However, the conclusions of these studies are contradictory. We aimed to determine the effect of statins on BCR of PCa using a systematic review and meta-analysis. Read More

View Article and Full-Text PDF

Stockholm3 - A new option to detect Prostate Cancer.

J Pak Med Assoc 2022 Apr;72(4):784

Medical College, Combined Military Hospital, Lahore, Pakistan.

View Article and Full-Text PDF

Cancer incidence and mortality and risk factors in member countries of the " Belt and Road " initiative.

BMC Cancer 2022 May 25;22(1):582. Epub 2022 May 25.

National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (Mailing address: 27 Nanwei Road, Xicheng District, Beijing, 100050, China.

Background: At present, "Belt and Road" ("B&R") member states (accounting for about 61.78% of the world's population) face different types of cancer threats to varying degrees. We analyzed the incidence and mortality and risk factors of cancer in the member countries of the "B&R" to explore the basis of health and medical cooperation between countries and provide a foundation for formulating cancer prevention and control policies for building a healthy "B&R. Read More

View Article and Full-Text PDF

Nrf2 antioxidant pathway and apoptosis induction and inhibition of NF-κB-mediated inflammatory response in human prostate cancer PC3 cells by Brassica oleracea var. acephala: An in vitro study.

Mol Biol Rep 2022 May 26. Epub 2022 May 26.

Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Background: Brassica oleracea var. acephala is a good source of health-promoting biologically active compounds like phenolics, vitamins, and glucosinolates.

Methods And Results: This in vitro research was conducted to evaluate the apoptotic, antioxidant, anti-inflammatory, and antiproliferative properties of ethanolic extract of Brassica oleracea var. Read More

View Article and Full-Text PDF

Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer.

Nat Commun 2022 May 25;13(1):2903. Epub 2022 May 25.

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, 210009, Nanjing, China.

Prostate cancer (PCa) is one of the most prevalent cancers in men worldwide, and hormonal therapy plays a key role in the treatment of PCa. However, the drug resistance of hormonal therapy makes it urgent and necessary to identify novel targets for PCa treatment. Herein, dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) is found and confirmed to be highly expressed in the PCa tissues and cells, and knock-down of DYRK2 remarkably reduces PCa burden in vitro and in vivo. Read More

View Article and Full-Text PDF

Prognostic significance of percentage Gleason grade 5 prostatic adenocarcinoma in needle biopsies from patients treated by radical prostatectomy.

Pathology 2022 May 22. Epub 2022 May 22.

The University of Queensland, Brisbane, Qld, Australia; Aquesta Uropathology, Brisbane, Qld, Australia.

Previous studies have shown that the percentage of high grade prostatic adenocarcinoma (Gleason patterns 4 and 5) in a biopsy correlates with outcome parameters. It has also been shown that the percentage Gleason pattern 4/5 tumour correlates with biochemical failure and overall survival. There are little data relating to the prognostic significance of quantifying the percentage of Gleason pattern 5 in isolation. Read More

View Article and Full-Text PDF

Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy.

Int J Urol 2022 May 25. Epub 2022 May 25.

Department of Urology, Akita University School of Medicine, Akita, Japan.

Objective: This study aimed to assess survival outcomes in older patients with de novo metastatic prostate cancer who initially received androgen deprivation therapy.

Methods: The retrospective multicenter study included 2784 men with metastatic prostate cancer who were treated with androgen deprivation therapy between 2008 and 2017. Patients were classified into <75, 75-79, and ≥80 age groups. Read More

View Article and Full-Text PDF

[Diagnostic Accuracy of Transperineal MRI-Ultrasound Fusion Biopsy at the Introduction Period].

Hinyokika Kiyo 2022 Apr;68(4):99-105

The Department of Urology, Kyoto University Hospital.

Magnetic resonance imaging (MRI) ultrasound fusion biopsy is becoming popular owing to the better detection rate of clinically significant prostate cancer (csPCa). We retrospectively evaluated the accuracy of MRI-targeted biopsy during the period of introduction at a single academic center by comparing findings of its specimen and whole-mount histopathology. Between June 2018 and January 2021, 106 transperineal MRI-ultrasound fusion biopsies using BioJet software were performed. Read More

View Article and Full-Text PDF

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.

J Immunother Cancer 2022 May;10(5)

Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway.

Background: Therapeutic cancer vaccines represent a promising approach to improve clinical outcomes with immune checkpoint inhibition. UV1 is a second generation telomerase-targeting therapeutic cancer vaccine being investigated across multiple indications. Although telomerase is a near-universal tumor target, different treatment combinations applied across indications may affect the induced immune response. Read More

View Article and Full-Text PDF

Stromal AR inhibits prostate tumor progression by restraining secretory luminal epithelial cells.

Cell Rep 2022 May;39(8):110848

Department of Molecular, Cell, and Developmental Biology, University of California, Santa Cruz, Santa Cruz, CA 95064, USA. Electronic address:

Androgen receptor (AR) is expressed in both the prostate epithelium and the prostate stroma and plays diverse roles in prostate physiology. Although low expression of stromal AR is clinically associated with advanced cancer stage and worse outcome, whether stromal AR inhibits or promotes prostate cancer progression remains controversial. Here, we specifically delete AR in smooth muscle cells of the adult mouse prostate under two tumorigenic conditions, namely, the Hi-Myc genetic model and the T + E2 hormonal carcinogenesis model. Read More

View Article and Full-Text PDF

Two-in-one: Portable piezoelectric and plasmonic exciton effect-based co-enhanced photoelectrochemical biosensor for point-of-care testing of low-abundance cancer markers.

Biosens Bioelectron 2022 May 20;211:114413. Epub 2022 May 20.

School of Advanced Manufacturing, Fuzhou University, Jinjiang, 362200, People's Republic of China.

In-depth exploration of the local surface plasmon resonance and piezoelectric effects associated with metal can help develop efficient biosensors. Here, we presented for the first time the localized surface plasmon resonance (LSPR) and piezoelectric effects co-enhance the construction of an efficient intra-body phase electric field for the construction of efficient photoelectrochemical (PEC) biosensors. Briefly, the LSPR enhancement and piezoelectric enhancement effects between Ag nanoparticles and the piezoelectric material NaNbO were investigated in a PEC biosensor system under the excitation of portable UV light. Read More

View Article and Full-Text PDF

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.

JCO Precis Oncol 2022 May;6:e2200085

Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka, Japan.

Purpose: Homologous recombination DNA repair deficiency (HRD) is associated with sensitivity to platinum and poly (ADP-ribose) polymerase inhibitors in certain cancer types, including breast, ovarian, pancreatic, and prostate. In these cancers, / alterations and genomic scar signatures are useful indicators for assessing HRD. However, alterations in other homologous recombination repair (HRR)-related genes and their clinical significance in other cancer types have not been adequately and systematically investigated. Read More

View Article and Full-Text PDF

Risk of Prostate Cancer in U.S. Veterans with Rheumatoid Arthritis.

Arthritis Care Res (Hoboken) 2022 Apr 5. Epub 2022 Apr 5.

VA Nebraska-Western Iowa Health Care System, Omaha, NE.

Objective: Patients with rheumatoid arthritis (RA) have an increased risk of select cancers, including lymphoma and lung cancer. Whether RA influences prostate cancer risk is uncertain. We aimed to determine the risk of prostate cancer in patients with RA compared to patients without RA in the Veterans Health Administration (VA). Read More

View Article and Full-Text PDF

Anti-cancer function of microRNA-30e is mediated by negative regulation of HELLPAR, a noncoding macroRNA, and genes involved in ubiquitination and cell cycle progression in prostate cancer.

Mol Oncol 2022 May 25. Epub 2022 May 25.

Burnett School of Biomedical Sciences, University of Central Florida, Orlando, Florida, USA.

Prostate cancer (PCa) progression relies on androgen receptor (AR) function, making AR a top candidate for PCa therapy. However, development of drug resistance is common, which eventually leads to development of castration-resistant PCa. This warrants a better understanding of the pathophysiology of PCa that facilitates the aberrant activation of key signaling pathways including AR. Read More

View Article and Full-Text PDF

Sedentary behavior and cancer-an umbrella review and meta-analysis.

Eur J Epidemiol 2022 May 25. Epub 2022 May 25.

Department of Epidemiology and Preventive Medicine, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.

Several systematic reviews and meta-analyses have summarized the association between sedentary behavior (SB) and cancer. However, the level of evidence and the potential for risk of bias remains unclear. This umbrella review summarized the current data on SB in relation to cancer incidence and mortality, with a particular emphasis on assessing the risk of bias. Read More

View Article and Full-Text PDF